OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-2.21%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$170M
AUM Growth
+$170M
(-11%)
Cap. Flow
-$12M
Cap. Flow
% of AUM
-7.07%
Top 10 Holdings %
Top 10 Hldgs %
56.85%
Holding
56
New
12
Increased
10
Reduced
12
Closed
16
Top Buys
| 1 |
Theravance Biopharma
TBPH
|
$5.04M |
| 2 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$4.97M |
| 3 |
Enanta Pharmaceuticals
ENTA
|
$3.02M |
| 4 |
SBBP
Strongbridge Biopharma plc.
SBBP
|
$2.78M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$2.66M |
Top Sells
Sector Composition
| 1 | Healthcare | 95.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $24.7M | 14.54% | 880,000 +95,000 | +12% | +$2.66M |
|
2
Axogen
AXGN
$743M
| $17.7M | 10.45% | 1,970,000 -30,000 | -2% | -$270K |
|
|
ARIA
3
DELISTED
Ariad Pharmaceuticals Inc
ARIA
| $12.4M | 7.33% | 1,000,000 -45,000 | -4% | -$560K |
|
|
GNMX
4
DELISTED
Aevi Genomic Medicine, Inc.
GNMX
| $7.77M | 4.58% | 1,500,000 -300,000 | -17% | -$1.55M |
|
5
FibroGen
FGEN
$47.8M
| $7.06M | 4.16% | 330,000 | – | – |
|
|
FOMX
6
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $5.5M | 3.24% | 495,000 -135,000 | -21% | -$1.5M |
|
7
Agios Pharmaceuticals
AGIO
$2.19B
| $5.43M | 3.2% | 130,000 | – | – |
|
8
Codexis
CDXS
$246M
| $5.38M | 3.17% | 1,170,000 | – | – |
|
|
CMRX
9
DELISTED
Chimerix, Inc.
CMRX
| $5.38M | 3.17% | 1,170,000 +390,000 | +50% | +$1.79M |
|
10
Neurogene
NGNE
$264M
| $5.12M | 3.02% | 310,000 | – | – |
|
|
11
Theravance Biopharma
TBPH
$699M
| $5.04M | 2.97% | +158,200 | New | +$5.04M |
|
|
MNTA
12
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $4.97M | 2.93% | +330,000 | New | +$4.97M |
|
|
ADMS
13
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $4.82M | 2.84% | 285,000 +35,000 | +14% | +$592K |
|
|
TVRD
14
Tvardi Therapeutics, Inc. Common Stock
TVRD
$281M
| $4.41M | 2.6% | 475,000 -200,000 | -30% | -$1.86M |
|
15
Prothena Corp
PRTA
$441M
| $4.06M | 2.39% | 82,500 +32,500 | +65% | +$1.6M |
|
|
LOXO
16
DELISTED
Loxo Oncology, Inc
LOXO
| $4.01M | 2.37% | 125,000 +15,000 | +14% | +$482K |
|
|
EGRX
17
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $3.97M | 2.34% | 50,000 -20,000 | -29% | -$1.59M |
|
18
PDS Biotechnology
PDSB
$57.8M
| $3.5M | 2.06% | 280,000 | – | – |
|
19
MacroGenics
MGNX
$112M
| $3.48M | 2.05% | 170,000 +25,000 | +17% | +$511K |
|
20
Xenon Pharmaceuticals
XENE
$2.98B
| $3.12M | 1.84% | 405,000 -5,000 | -1% | -$38.5K |
|
|
21
Enanta Pharmaceuticals
ENTA
$180M
| $3.02M | 1.78% | +90,000 | New | +$3.02M |
|
|
SBBP
22
DELISTED
Strongbridge Biopharma plc.
SBBP
| $2.78M | 1.64% | +1,160,000 | New | +$2.78M |
|
23
Omeros
OMER
$283M
| $2.63M | 1.55% | +265,300 | New | +$2.63M |
|
24
Clearside Biomedical
CLSD
$28.9M
| $2.41M | 1.42% | +270,000 | New | +$2.41M |
|
25
Iovance Biotherapeutics
IOVA
$807M
| $2.09M | 1.23% | 300,000 +20,000 | +7% | +$139K |
|